Rezolute, Inc. (RZLT) Presents At Morgan Stanley 23rd Annual Global Healthcare Conference TranscriptSeeking Alpha • 09/12/25
Rezolute Announces Alignment with FDA on Streamlined Design for Ongoing Phase 3 Trial of Ersodetug in Tumor HyperinsulinismGlobeNewsWire • 09/02/25
Rezolute Appoints Seasoned Commercial Executive Sunil Karnawat as Chief Commercial OfficerGlobeNewsWire • 08/20/25
Rezolute Announces Presentation of Participant Baseline Data from its Fully Enrolled Phase 3 Study of Ersodetug in Congenital Hyperinsulinism at the Upcoming Annual Meeting of the Endocrine Society (ENDO 2025)GlobeNewsWire • 07/09/25
Rezolute Announces Completion of Enrollment in the Phase 3 sunRIZE Study of Ersodetug in Patients with Congenital HyperinsulinismGlobeNewsWire • 05/28/25
Rezolute Reports Third Quarter Fiscal 2025 Financial Results and Provides Business UpdateGlobeNewsWire • 05/13/25
Rezolute Receives Breakthrough Therapy Designation from FDA for Ersodetug in the Treatment of Hypoglycemia Due to Tumor HyperinsulinismGlobeNewsWire • 05/05/25
Rezolute 'Thrilled' With Positive Review Of Genetic Disorder Trial, Expects Topline Results In DecemberBenzinga • 04/23/25
Rezolute Announces Pricing of Offering of $90 Million of Common Stock and Pre-Funded WarrantsGlobeNewsWire • 04/23/25
Rezolute Announces Positive Recommendation After Independent Interim Analysis of Phase 3 sunRIZE Study of Ersodetug in Congenital Hyperinsulinism (“HI”)GlobeNewsWire • 04/23/25
Rezolute (RZLT) Upgraded to Buy: What Does It Mean for the Stock?Zacks Investment Research • 04/11/25
Rezolute Announces Appointment of Rare Disease Commercial Leader Erik Harris to its Board of DirectorsGlobeNewsWire • 03/26/25
Rezolute Reports Second Quarter Fiscal 2025 Financial Results and Provides Business UpdateGlobeNewsWire • 02/12/25
Rezolute Provides Update on its Phase 3 sunRIZE Study of Ersodetug for the Treatment of Hypoglycemia Due to Congenital HyperinsulinismGlobeNewsWire • 02/04/25
Here's Why 'Trend' Investors Would Love Betting on Rezolute (RZLT)Zacks Investment Research • 01/07/25
RZLT Stock Rises on FDA's Orphan Designation for Rare Disease DrugZacks Investment Research • 12/04/24